VISEN Pharmaceuticals operates as a biopharmaceutical company. The company is headquartered in Suzhou, Jiangsu and currently employs 54 full-time employees. The company went IPO on 2025-03-21. The firm's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The firm is in the late stage of research and development, and its products are close to commercialization.
02561.HK stock price ended at $33.8 on 금요일, after dropping 1.80%
On the latest trading day Jan 16, 2026, the stock price of 02561.HK fell by 1.80%, dropping from $34.32 to $33.80. During the session, the stock saw a volatility of 3.69%, with prices oscillating between a daily low of $33.10 and a high of $34.32. On the latest trading day, the trading volume for 02561.HK decreased by 15.4K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 15.6K shares were traded, with a market value of approximately $3.8B.
02561.HK 기술적 시그널
기술적 시그널 요약
구매 신호 1
중립 신호 2
매도 신호 4
Strong Sell
Sell
Neutral
Buy
Strong Buy
02561.HK은 현재 1개의 매수 신호와 4개의 매도 신호를 보이고 있습니다. 이 주식은 12:00 AM 이후로 하락 추세 상태에 있으며, 이 기간 동안 총 가격 변동률은 -1.8%입니다. 전반적으로 기술적 지표들은 중기적으로 Sell 전망을 나타내고 있습니다.
02561.HK에 대한 강세/약세 신호
이동평균, RSI, MACD, 거래량 등 핵심 지표를 분석하여 02561.HK 의 강세/약세 시그널을 생성합니다. 이 인사이트를 활용해 더 현명한 투자 결정을 내리세요.